Arcadia Biosciences, Inc. (RKDA) - Dilution Analysis

10-Q filing | 2.1M shares outstanding

10-K filing | 2.1M shares outstanding

10-Q filing | 1.4M shares outstanding

8-K filing: Arcadia Biosciences reported that Above Food Corp. has not made a required payment of $2 million of principal and approximately $475,000 of interest under a promissory note, and has not delivered approximately 3.5 million Prepayment Shares following a notice delivered by Arcadia.

10-Q filing | 1.4M shares outstanding

10-K filing | 1.4M shares outstanding

10-Q filing | 1.4M shares outstanding

10-Q filing | 1.4M shares outstanding

10-Q filing | 1.4M shares outstanding

10-K filing | 1.2M shares outstanding

10-Q filing | 1.1M shares outstanding

10-Q filing | 1.1M shares outstanding

10-Q filing | 0.9M shares outstanding

S-3 filing: This prospectus covers the sale or other disposition from time to time of up to 2,032,319 shares of our common stock, $0.001 par value per share, by the selling stockholders identified in this prospectus.

10-K filing | 0.9M shares outstanding

8-K filing: Arcadia Biosciences, Inc. entered into a securities purchase agreement for a private placement involving the sale and issuance of common stock, pre-funded warrants, and investment options. ($6.0M proceeds)

8-K filing: Stock split 1-for-40 | Outstanding: 24,552,543 → 613,813

8-K filing: Arcadia Biosciences declared a dividend of Series A Preferred Stock for each outstanding share of common stock and approved an amendment to the Amended and Restated Bylaws to lower the quorum requirement for stockholder meetings.

10-Q filing | 24.6M shares outstanding

8-K filing: Arcadia Biosciences, Inc. completed a registered direct offering of 4,722,506 shares of common stock and pre-funded warrants at $1.05876 per share, along with issuing unregistered preferred investment options to purchase up to 4,722,506 shares and placement agent investment options to purchase up to 236,125 shares. ($5.0M proceeds)

10-Q filing | 22.2M shares outstanding

10-Q filing | 22.2M shares outstanding

S-3 filing: Arcadia Biosciences, Inc. is filing an S-3 to offer and sell up to an aggregate amount of $50,000,000 of any combination of common stock, preferred stock, warrants, or units.

10-K filing | 22.2M shares outstanding

S-1 filing: Resale of common stock issuable upon exercise of outstanding warrants by selling stockholders.

10-Q filing | 22.2M shares outstanding

10-Q filing | 22.2M shares outstanding

8-K filing: Arcadia Biosciences, Inc. purchased substantially all assets of Sellers for the aggregate purchase price of: (i) $4,000,000, and (ii) 827,400 unregistered shares of Arcadia's common stock.

10-Q filing | 21.3M shares outstanding

10-K filing | 21.3M shares outstanding

S-3 filing: This S-3 filing registers 12,209,015 shares of common stock for sale by selling stockholders.

8-K filing: Arcadia Biosciences, Inc. closed a private placement on January 28, 2021, issuing 7,876,784 shares of common stock at $3.1925 per share and warrants exercisable for 3,938,392 shares at $3.13 per share. ($25.15M proceeds)

8-K filing: Arcadia Biosciences, Inc. entered into a securities purchase agreement for the offering and sale of 2,618,658 shares of common stock at $2.93 per share, along with warrants to purchase 2,618,658 shares at $0.125 per share with an exercise price of $3.00 per share, closing expected on December 22, 2020. ($7.99M proceeds)

8-K filing: Arcadia Biosciences sold its membership interests in Verdeca, LLC to Bioceres Crop Solutions Corp. for $5,000,000 in cash and 1,875,000 shares of BIOX common stock. ($5.0M proceeds)

10-Q filing | 10.7M shares outstanding

10-Q filing | 10.7M shares outstanding

S-3/A filing: This S-3/A filing registers 2,135,449 shares of common stock for sale by selling shareholders, with the last reported sale price at $3.72 per share on August 7, 2020.

S-3/A filing: This is an S-3/A filing to update the section entitled "Incorporation of Information by Reference" and to file an updated Exhibit 23.1.

8-K filing: Arcadia Biosciences, Inc. closed the exercise of existing warrants and the issuance of new warrants on July 8, 2020, resulting in gross proceeds of approximately $2.55 million. ($2.55M proceeds)

8-K filing: Arcadia Biosciences, Inc. entered into a letter agreement with an existing accredited investor to exercise warrants to purchase up to 641,416 shares of the Company's common stock at an exercise price of $3.975 per share, with gross proceeds expected to be approximately $2.55 million. ($2.55M proceeds)

S-3 filing: This is an S-3 filing for the sale of up to 1,461,962 shares of common stock by selling shareholders.

8-K filing: Arcadia Biosciences, Inc. closed the exercise of warrants on May 18, 2020, issuing 1,392,345 shares of common stock for gross proceeds of approximately $6.82 million. ($0.0M proceeds)

8-K filing: Arcadia Biosciences, Inc. entered into letter agreements with existing accredited investors to exercise warrants to purchase up to 1,392,345 shares of common stock at $4.90 per share, with gross proceeds expected to be approximately $6.82 million. ($6.82M proceeds)

10-Q filing | 8.7M shares outstanding

10-K filing | 8.7M shares outstanding